Democritus University of Thrace (DUTH)
Μια συγκριτική μελέτη μεταβολών κυτταροκινών στο βρογχοκυψελιδικό έκλπυμα ασθενών με ιδιοπαθή πνευμονική ίνωση πριν και μετά από θεραπεία με ιντερφερόνη γ-1b και κορτικοστεροειδή ή αζαθειοπρίνη και κορτικοστεροειδή - Μια προοπτική, τυχαιοποιημένη, πανελλήνια μελέτη
Abstract
dc:descriptionBackground: Idiopathic pulmonary fibrosis (IPF) is a fatal lung disorder, the etiology of which is unknown and there is no effective therapy. Combination of corticosteroid and immunosuppressive agents as azathioprine (AZA) or antifibrotic drugs as interferone γ-1b (IFN-γ-1b) have been suggested. Several studies have shown that Th2 cytokines are predominately involved in mediating chronic fibroproliferative disorders such as IPF, whereas Th1 cytokines are downregulated. Moreover,profibrotic mediators such as CTGF and TGFb induce fibroblast activation, collagen synthesis and finally fibrosis. The role of alveolar macrofages in the expression of these cytokines remains unclear. Aim: The aim of the present study was a) to evaluate of the expression of theTh1 cytokines IFN-γ-1b, IL-18 and TNFα, the Th2 cytokine IL-4 and the profibrotic growth factors CTGF and TGFβ in macrophages from bronchoalveolar lavage fluid(BALF) of IPF patients, comparing to control group b) to compare the effectiveness of treatment with interferon g plus low dose prednisone versus azathioprine plus low dose prednisone in patients with IPF, and to investigate whether the two therapeutic options can modulate the cellular apoptotic profile in patients with IPF. Materials & Methods: Bronchoalveolar lavage fluid (BALF) samples derived from 20 newly diagnosed IPF patients before and after six months of treatment with either interferon (IFN-γ-1b) and prednizolone (n=10 patients) or azathioprine (AZA)and prednizolone (n=10 patients) and also BALF samples from 10 normal subjects(control group) were used for the analysis of IL-18, IFNγ, IL-4, CTGF, TGFb and TNFα protein expression in the alveolar macrophages. Furthermore, the effectiveness of these regimens on pulmonary function tests (FEV1, FVC, DLCO), on PaO2 andPaCO2 and on HRCT of the IPF patients was investigated. Results: The two patients groups showed no statistically significant difference regarding the course of the disease after 6 month therapy . In particular, there was no difference referring to FEV1%, FVC%, DLCO% and PaO2, PaCO2 values after treatment with both regimens. Moreover, evaluation of the fibrosis extent in HRCT showed no difference before and after therapy in the two patients groups. Decreased CTGF protein expression was identified in IPF patients correlating to control group(p=0.001) while the two patients groups had similar CTGF expression which remained unchanged after therapy. IL-18, IFNγ, IL-4, TGFb and TNFα, expression inIPF patients did not differ from normal subjects. Neither of the regimens affected those factors’ protein expression. Conclusion: Our findings suggest that the alveolar macrophages are not the main source of CTGF and TNFα in IPF. Moreover, therapeutic intervention with either AZA or IFN-γ-1b did not result in significant change of these factors’ protein expression or the clinical course of the disease.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2011
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Xifteri, Areti
- Ξυφτέρη, Αρετή
Subjects
dc:subject × 16- Ιδιοπαθής πνευμονική ίνωση
- Βρογχοκυψελιδικό έκπλυμα
- Κυτταροκίνες
- Μακροφάγα
- Αζαθειοπρίνη
- Ιντερφερόνη γάμμα 1-β
- Idiopathic pulmonary fibrosis (IPF)
- Bronchoalveoral lavage
- Cytokines
- Macrophages
- Azathioprine
- Interferon gamma-1b
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/26098